Stylized illustration: A corporate principal under a tsunami of legal documents

Scientology billionaire Bob Duggan and his pharmaceutical company Summit Therapeutics are now facing a tsunami of legal threats due to allegations of serious misconduct.

When fourteen plaintiffs’ firms across thirty-nine months independently invest time into investigating the same company, the convergence is not coincidence. It is a documentary record of the sophisticated securities bar’s collective assessment that material misstatements or omissions exist in the public filings of Bob Duggan’s Summit Therapeutics (NASDAQ symbol SMMT). 

The convergence reached critical mass at the moment of the auditor-required going-concern disclosure in Summit’s April 30, 2026 Form 10-Q. Bob Duggan’s own outside auditor reported this in SMMT’s 10-Q: 

“We [Summit Therapeutics] do not currently have sufficient working capital to fund our planned operations for the next twelve months. There is uncertainty regarding our ability to raise additional capital and as such, there is substantial doubt regarding our ability to continue as a going concern.”

May 1, 2026 also saw a massive sell off of SMMT stock just before market close and in after hours trading. As we reported, SMMT stock lost ~28% of its value on May 1, 2026 before settling to a -24.9% one day loss: 

As SMMT’s largest shareholder, Bob Duggan lost about $3.23 billion in a single day in the value of his SMMT holdings. This figure is based on $3.04 billion in direct holdings plus another $191 million on indirect holdings with a share price of $16.12 when we calculated the number. It was a wipeout. 

The same pattern of law firms seeking to file class actions preceded the federal enforcement action against David Gentile’s GPB Capital Holdings. We are not saying that is necessarily the case here with Bob Duggan, but it is easy to predict that the SEC will become involved in SMMT.

In our opinion, Duggan’s big risks are a) placing Summit Therapeutics into bankruptcy within 12 months, b) litigation with Akeso, and c) the Janssen Federal case. In the last matter, former  Janssen Global Services, LLC employee Cynthia Nwachukwu is alleged to have downloaded  7,185 files containing trade secrets on anti-cancer drug research, market strategies, etc. Nwachukwu then went to work for Summit Therapeutics. Janssen, a subsidiary of Johnson & Johnson filed a lawsuit alleging trade secret theft and other causes of action. Janssen has argued that the files Nwachukwu is alleged to have stolen would be of enormous benefit to Summit Therapeutics.

The Summit Therapeutics architecture we documented in November 2023 included the controlled-company exemption; the Type III modification recognizing $851 million in executive equity benefit; the related-party network; the undisclosed Janssen federal litigation; the active Rainaldi derivative action;  and now the auditor-required going-concern qualification all sit on top of one another in the public record.

Plaintiffs’ firms are now advertising for Summit lead plaintiffs because the stock price dropped 24.91% on May 1, 2026. They are advertising because the architecture that produced the May 1 disclosure has been sitting in the public filings for thirty-nine months, and they have spent that time assembling the predicate facts.

The Documentary Record

February 27, 2023 — Kaskela Law LLC. Philadelphia firm Kaskela Law announced a stockholder investigation of Summit Therapeutics six weeks after the January 2023 closing of the Akeso License Agreement and approximately one month after the 2023 Rights Offering completed. The investigation sought to determine whether Summit had “issued false and misleading statements and/or failed to disclose material facts to its investors.” This was the first publicly announced plaintiffs’ bar investigation of Summit in the Duggan-Akeso era.

February 26, 2024 — Bronstein, Gewirtz & Grossman, LLC. New York firm Bronstein Gewirtz announced an investigation of Summit explicitly citing two specific disclosures: Summit’s report that the maturity date for “a $100 million note from its chairman and Chief Executive Officer had been extended from September 6, 2024 to April 1, 2025,” and Summit’s filing of “a mixed shelf registration statement for the potential sale of up to $450 million of its securities.” The Bronstein Gewirtz investigation publicly identified the December 2022 Notes self-dealing structure as a potential securities fraud predicate.

March 11, 2024 — Pomerantz LLP. Pomerantz, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, opened a parallel investigation citing the same $100 million note extension and shelf filing. Pomerantz is generally regarded as one of the leading plaintiffs’ securities class action firms in the country. Its public investigation announcement on Summit was the moment when sophisticated securities counsel began publicly assembling the predicate facts for what would become the current consolidated class action.

June 23, 2025 — Pomerantz LLP, expansion. Pomerantz expanded its investigation to cover Summit’s May 30, 2025 HARMONi clinical trial disclosure. On that date, Summit announced topline results from the global Phase III HARMONi study showing that ivonescimab combined with chemotherapy “failed to make a statistically significant difference in overall survival.” Summit’s stock price fell $7.99 per share, or 30.5%, on the same day, closing at $18.22. The Pomerantz announcement specifically cited the OS-miss event as a fraud predicate.

June 6, 2025 — The Portnoy Law Firm. Los Angeles firm The Portnoy Law Firm announced its investigation of Summit. Lead attorney Lesley F. Portnoy.

July 14, 2025 — The Schall Law Firm. Los Angeles firm The Schall Law Firm opened an investigation citing the same May 30, 2025 HARMONi disclosure and the 30.5% same-day stock price decline. Brian Schall, lead attorney.

August 12, 2025 — The Schall Law Firm, lead plaintiff solicitation. Schall transitioned from an investigation announcement to a formal lead plaintiff solicitation, announcing that a class action lawsuit had been filed against Summit Therapeutics for “violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.” Class period: March 17, 2022 to September 22, 2022. This was the first confirmed filed class action against Summit. The class period covered Summit’s disclosures regarding the Pinnacle Study of poziotinib, an earlier Summit clinical asset that preceded the Akeso transaction. Lead plaintiff deadline: September 24, 2025.

September 9, 2025 — The Portnoy Law Firm, deadline reminder. Portnoy issued a deadline reminder for the September 24, 2025 lead plaintiff motion deadline.

October 3, 2025 — Pomerantz LLP, second update. Pomerantz issued a second investigation update covering both the May 30, 2025 HARMONi event and Summit’s September 7, 2025 announcement of additional HARMONi data showing weaker results in North American and European patients than in Asian patients.

October 18, 2025 — Pomerantz LLP, third update. Pomerantz issued a third investigation update on Summit, indicating continued active analysis and lead plaintiff outreach.

The Three-Front Legal War

The plaintiffs’ bar is now one of three independent legal actions moving against Summit Therapeutics simultaneously.

The first is the Rainaldi Revocable Trust derivative action filed March 17, 2025 in the Delaware Court of Chancery, which seeks rescission of the shares Duggan and Zanganeh received as prepaid interest on the December 2022 Notes. The motion-to-dismiss briefing schedule was filed with the courts on April 16, 2026. The case is moving substantively forward.

The second is the Janssen Global Services, LLC v. Cynthia Nwachukwu federal trade-secrets case, Case No. 3:26-CV-02563-MAS-TJB, filed in the United States District Court for the District of New Jersey on March 12, 2026. Janssen alleges Nwachukwu downloaded approximately 7,185 files of Janssen “highly sensitive Company documents and proprietary and trade secret information” before her resignation from Janssen and her subsequent employment at Summit. Janssen filed a Rule 26(d) motion for expedited discovery on March 27, 2026, seeking depositions and document production specifically about Nwachukwu’s responsibilities and activities at Summit. Notably, the Janssen case is not disclosed in Summit’s April 30, 2026 Form 10-Q legal proceedings section.

The third is the consolidated securities class action proceeding in federal court covering the Pinnacle Study disclosures from 2022, with the Pomerantz HARMONi OS-miss investigation in pre-filing posture and the going-concern event creating the conditions for a new class action covering the ivonescimab disclosures.

The plaintiffs’ bar has been positioned for this exact convergence for over a year. Multiple firms are now actively advertising for lead plaintiffs. The architecture we documented in November 2023 — Bob Duggan operating a self-dealing structure that shifts risk onto outside investors while preserving his upside — is the architecture that fourteen plaintiffs’ firms across thirty-nine months have publicly identified as a potential securities fraud predicate.

The History of a Drug Deal Gone Bad

In 2022, Bob Duggan loaned his company Summit Therapeutics $500 million to allow the firm to purchase the rights to an investigational anti-cancer drug called Ivonescimab. Phil Taylor of Pharmaphorum reported on the deal:

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but, in fact, it comes from diminutive biotech Summit Therapeutics. 

The Anglo-US company – which ended its last financial quarter with cash and equivalents of less than $140 million – is financing the licensing deal for Chinese biotech Akeso’s PD-1 and VEGF-targeting bispecific antibody ivonescimab with debt and a $500 million rights offering, due to take place early next year.

The debit facility is being provided by Summit’s co-chief executives Bob Duggan and Maky Zanganeh, both veterans of Pharmacyclics who pocketed rich rewards when the company was sold to AbbVie for $21 billion in 2015.

In November 2023, we published an analysis documenting how Bob Duggan structured the December 2022 Akeso License Agreement to eliminate his personal financial risk through a $520 million bridge financing arrangement to himself and Dr. Mahkam Zanganeh, repaid through a 2023 Rights Offering at $1.05 per share. The analysis concluded that Duggan was shifting risk onto outside investors while preserving his upside.

Securities class action firms reached the same conclusion. The first plaintiffs’ bar investigation of Summit Therapeutics was opened in February 2023, six weeks after the Akeso transaction closed. Multiple firms have followed since.

Summit Therapeutics trumped the Akeso deal in its December 6, 2022 press release: 

Summit Therapeutics printed this explicit disclaimer: 

After paying the $500 million licensing fee for ivonescimab, Bob Duggan had to raise money for Summit Therapeutics to a) repay himself, and b) pay his scientific staff to up-engineer the Chinese ivonescimab to Western standards. Duggan then had to get his American variant of ivonescimab successfully through FDA clinical trials; obtain FDA approval to sell ivonescimab; and then watch the billions of dollars roll in from sales of his potent anti-cancer drug. However, this has not happened.

Getting a new drug to market is an incredibly expensive undertaking and so Bob Duggan raised money by selling shares in Summit Therapeutics (Nasdaq symbol SMMT). Progress did not go as planned and ivonescimab has not made it through clinical trials to a level of efficacy required for FDA approval. 

When Bob Duggan purchased the rights for ivonescimab, it was for United States, Canada, Europe, Japan, Latin America (including Mexico and all countries in Central America, South America, and the Caribbean), the Middle East, and Africa. Akeso was licensed for the rest of the world.

SMMT’s website included the statement, “All Akeso ivonescimab clinical trials are being conducted in China and/or Australia and are fully sponsored and managed by Akeso.” This created a downstream concern that the Chinese clinical trials of ivonescimab would not be conducted with the same rigor as are US clinical trials.

This appeared to be what happened. The published Chinese clinical results of ivonescimab which were optimistic and promising — and were announced by Summit Therapeutics — could not be reproduced in US clinical trials. This was a disaster for Summit as repeatability of results in any lab in the world is one of keystones of science. Had Akeso China deliberately skewed the tests or was it poor Chinese science?

Akeso is ultimately controlled by the Chinese Communist Party. Therefore, we have a Scientologist Bob Duggan ultimately doing business with the CCP, this despite the fact that L. Ron Hubbard was a staunch anti-Communist. To this day, the Church of Scientology does not accept Communists as members and “Are you a Communist?” remains a sec check question.

As we asked in November, 2023, did Bob Duggan make a bad $500 million bet by partnering with a Chinese pharma firm? This question is an especially relevant one to ask given the fact that, at the time, China’s Covid-19 vaccine was deemed ineffective according to Dr. Anthony Fauci. Given its vast resources, the PRC’s failure to make a vaccine on a par with the West forces any analyst to ask if Akeso, Inc. can actually come through for Summit Therapeutics.

The chain of ownership of Akeso Inc. from top to bottom: 

The Charoen Pokphand Group Company, Ltd. a/k/a the CP Group is a Thai conglomerate based in Bangkok. The conglomerate owns >200 businesses in Mainland China. 2022 Revenues are reported as $82 billion.

The CP Group is Thailand’s largest private company and the largest privately held Royal Warrant holder of the Thai Royal Family.

The CP Group owns Sino Biopharmaceutical Limited a/k/a Sino Biopharm which is located in Mainland China.

Sino Biopharm owns Chia Tai Tianqing Pharmaceutical Group Co., Ltd. a/k/a CTTQ is a multinational pharmaceutical company based in Mainland China. It is one of the shareholders of CTTQ Akeso. CTTQ is located in Shanghai, China.

CTTQ-Akeso Biomed. Tech. Co., Ltd (正大天晴康方(上海)生物醫藥科 技有限公司), a limited liability company incorporated under the laws of the PRC on August 30, 2019. CTTQ owns part of CTTQ-Akeso.

Akeso Biopharma Co., Ltd.

Akeso, Inc. (康方生物科技(開曼)有限公司), is a limited liability incorporated in the Cayman Islands on January 30, 2019.

Summit Therapeutics April 30, 2026 10Q: